<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03230318</url>
  </required_header>
  <id_info>
    <org_study_id>DZB-CS-301</org_study_id>
    <secondary_id>ARQ 087-301</secondary_id>
    <nct_id>NCT03230318</nct_id>
  </id_info>
  <brief_title>Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma</brief_title>
  <acronym>FIDES-01</acronym>
  <official_title>A Pivotal Study of Derazantinib in Patients With Inoperable or Advanced Intrahepatic Cholangiocarcinoma and FGFR2 Gene Fusions or FGFR2 Gene Mutations or Amplifications</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Basilea Pharmaceutica</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Basilea Pharmaceutica</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pivotal, open-label, single-arm study will evaluate the anti-cancer activity of&#xD;
      derazantinib by Objective Response Rate (ORR) by central radiology review as per RECIST v1.1&#xD;
      in subjects with inoperable or advanced intrahepatic cholangiocarcinoma (iCCA) whose tumors&#xD;
      harbor FGFR2 gene fusions (by FISH performed by the central laboratory) or FGFR2 gene&#xD;
      mutations or amplifications (based on NGS testing performed or commissioned by the respective&#xD;
      study center) and who received at least one prior regimen of systemic therapy. Subjects will&#xD;
      be dosed orally once per day at 300 mg of derazantinib capsules.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 10, 2017</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Substudy 1: Anti-cancer activity of derazantinib by Objective Response Rate (ORR)</measure>
    <time_frame>Up to approximately 32 weeks</time_frame>
    <description>ORR will be assessed by central radiology review as per RECIST version 1.1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Substudy 2: Anti-tumor activity of derazantinib by Progression Fress Survival at 3 months (PFS 3)</measure>
    <time_frame>3 months</time_frame>
    <description>PFS 3 will be assessed based on survival status or central radiology review (Response Evaluation Criteria in Solid Tumors, RECIST 1.1)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of derazantinib as assessed by adverse events</measure>
    <time_frame>Up to approximately 36 weeks</time_frame>
    <description>Adverse events will be graded using NCI CTCAE guidelines, version 4.03</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-cancer activity of derazantinib by duration of response (DoR)</measure>
    <time_frame>Up to approximately 32 weeks</time_frame>
    <description>DoR will be assessed by central radiology review per RECIST version 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-cancer activity of derazantinib by progression free survival (PFS)</measure>
    <time_frame>Up to approximately 32 weeks</time_frame>
    <description>PFS will be assessed by central radiology review per RECIST version 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-cancer activity of derazantinib by overall survival (OS)</measure>
    <time_frame>Up to approximately 36 weeks</time_frame>
    <description>OS will be calculated from the first date of receiving study drug until death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life as assessed by the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 questionnaire</measure>
    <time_frame>Up to approximately 36 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life as assessed by the EORTC QLQ-BIL21 questionnaire</measure>
    <time_frame>Up to approximately 36 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life as assessed by the EuroQol EQ-5D questionnaire</measure>
    <time_frame>Up to approximately 36 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Substudy 2: Anti-cancer activity of derazantinib by Objective Response Rate</measure>
    <time_frame>Up to approximately 32 weeks</time_frame>
    <description>ORR will be assessed by central radiology review as per RECIST version 1.1</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">143</enrollment>
  <condition>Intrahepatic Cholangiocarcinoma</condition>
  <condition>Combined Hepatocellular and Cholangiocarcinoma</condition>
  <arm_group>
    <arm_group_label>derazantinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>derazantinib</intervention_name>
    <description>derazantinib will be orally administered at 300 mg once per day one hour prior to or two hours after a meal and is supplied as 100 mg capsules.</description>
    <arm_group_label>derazantinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed written informed consent granted prior to initiation of any study-specific&#xD;
             procedures&#xD;
&#xD;
          2. 18 years of age or older&#xD;
&#xD;
          3. Histologically or cytologically confirmed locally advanced, inoperable (where surgery&#xD;
             is not indicated due to disease extension, co-morbidities, or other technical&#xD;
             reasons), or metastatic iCCA or mixed histology tumors (combined&#xD;
             hepatocellular-cholangiocarcinoma [cHCC-CCA])&#xD;
&#xD;
          4. Substudy 1: FGFR2 fusion status based on the following assessments:&#xD;
&#xD;
             a) If central laboratory designated by Sponsor: Positive FISH test; and/or b) If&#xD;
             non-central laboratory: i) Positive FISH or NGS test: patients may be enrolled and may&#xD;
             start dosing, but central confirmation is required* ii) Negative FISH or NGS test:&#xD;
             tissue may be submitted to the central laboratory designated by the Sponsor, and&#xD;
             patients may only be enrolled if the central test is positive&#xD;
&#xD;
             *Using standard protocols and approved by local IRB/EC, by CLIA or other similar&#xD;
             agency.&#xD;
&#xD;
             Substudy 2: FGFR2 mutation/amplification status based on local NGS testing performed&#xD;
             or commissioned by the respective study site.&#xD;
&#xD;
          5. Received at least one regimen of prior systemic therapy and then experienced&#xD;
             documented radiographic progression&#xD;
&#xD;
          6. Measurable disease by RECIST version 1.1 criteria&#xD;
&#xD;
          7. ECOG performance status ≤ 1&#xD;
&#xD;
          8. Adequate organ functions as indicated by the following laboratory values (based on&#xD;
             screening visit values from the central laboratory).&#xD;
&#xD;
               -  Hematological&#xD;
&#xD;
                    -  Hemoglobin (Hgb) ≥ 9.0 g/dL&#xD;
&#xD;
                    -  Absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L&#xD;
&#xD;
                    -  Platelet count ≥ 75 x 109/L&#xD;
&#xD;
                    -  International normalized ratio (INR) 0.8 to upper limit of normal (ULN) or ≤&#xD;
                       3 for subjects receiving anticoagulant therapy such as Coumadin or heparin&#xD;
&#xD;
               -  Hepatic&#xD;
&#xD;
                    -  Total bilirubin ≤ 2 x ULN&#xD;
&#xD;
                    -  AST and ALT ≤ 3 ULN (≤ 5 x ULN for subjects with liver metastases)&#xD;
&#xD;
                    -  Albumin ≥ 2.8 g/dL&#xD;
&#xD;
               -  Renal&#xD;
&#xD;
                    -  Serum creatinine ≤ 1.5 x ULN&#xD;
&#xD;
                    -  Creatinine clearance of ≥ 30 mL/min as estimated by the Cockcroft-Gault&#xD;
                       equation&#xD;
&#xD;
          9. Female and male patients of child-producing potential must agree to avoid becoming&#xD;
             pregnant or impregnating a partner, respectively, use double-barrier contraceptive&#xD;
             measures, oral contraception, or avoidance of intercourse, during the study*, and&#xD;
             until at least 120 for 90 days after the last dose of derazantinib.&#xD;
&#xD;
             *From the day of first study medication, or for oral contraception from 14 days before&#xD;
             first study medication.&#xD;
&#xD;
             Male patients are considered not to be of child-producing potential if they have&#xD;
             azoospermia (whether due to vasectomy or an underlying medical condition). Female&#xD;
             patients are considered not to be of child-producing potential if they are:&#xD;
&#xD;
               -  postmenopausal* , or&#xD;
&#xD;
               -  have had a hysterectomy and/or bilateral oophorectomy, bilateral salpingectomy or&#xD;
                  bilateral tubal ligation/occlusion, at least 6 weeks prior to screening, or&#xD;
&#xD;
               -  have a congenital or acquired condition that prevents childbearing.&#xD;
&#xD;
             Male or female patients of child-producing potential must agree to comply with one of&#xD;
             the following until at least 120 days after the last dose of derazantinib:&#xD;
&#xD;
               1. Abstinence from heterosexual activity**&#xD;
&#xD;
               2. Using (or having their partner use) an acceptable method of contraception during&#xD;
                  heterosexual activity. Acceptable methods of contraception are***:&#xD;
&#xD;
                    -  any ONE of:&#xD;
&#xD;
                       - an intrauterine device (IUD)&#xD;
&#xD;
                       - vasectomy of a female patient's male partner&#xD;
&#xD;
                       - a contraceptive rod implanted into the skin.&#xD;
&#xD;
                    -  any TWO in combination of:&#xD;
&#xD;
                       - diaphragm with spermicide (cannot be used in conjunction with cervical&#xD;
                       cap/spermicide)&#xD;
&#xD;
                       - cervical cap with spermicide (nulliparous women only)&#xD;
&#xD;
                       - contraceptive sponge (nulliparous women only)&#xD;
&#xD;
                       - male condom or female condom (cannot be used together)&#xD;
&#xD;
                       - hormonal contraceptive (oral contraceptive pill [estrogen/progestin pill&#xD;
                       or progestin-only pill], contraceptive skin patch, vaginal contraceptive&#xD;
                       ring, or subcutaneous contraceptive injection)&#xD;
&#xD;
                       *Postmenopausal is defined as at least 12 months with no menses without an&#xD;
                       alternative medical cause; in women &lt; 45 years of age a high follicle&#xD;
                       stimulating hormone (FSH) level in the postmenopausal range may be used to&#xD;
                       confirm a post -menopausal state in women not using hormonal contraception&#xD;
                       or hormonal replacement therapy. In the absence of 12 months of amenorrhea,&#xD;
                       a single FSH measurement is not sufficient.&#xD;
&#xD;
                         -  Abstinence (relative to heterosexual activity) can be used as the sole&#xD;
                            method of contraception if it is consistently employed as the subject's&#xD;
                            preferred and usual lifestyle and if considered acceptable by local&#xD;
                            regulatory agencies and ERCs/IRBs. Periodic abstinence (e.g., calendar,&#xD;
                            ovulation, sympto-thermal, post-ovulation methods, etc.) and withdrawal&#xD;
                            are not acceptable methods of contraception.&#xD;
&#xD;
                              -  If a contraceptive method listed above is restricted by local&#xD;
                                 regulations/guidelines, then it does not qualify as an acceptable&#xD;
                                 method of contraception for subjects participating at sites in&#xD;
                                 this country/region.&#xD;
&#xD;
             Exclusion Criteria:&#xD;
&#xD;
          1. Receipt of treatment before the first dose of study drug (Cycle 1 Day 1) within an&#xD;
             interval shorter than the following, as applicable:&#xD;
&#xD;
               -  One chemotherapy or biological (e.g., antibody) cycle interval&#xD;
&#xD;
               -  Five half-lives of any small-molecule investigational or licensed medicinal&#xD;
                  product&#xD;
&#xD;
               -  Two weeks, for any investigational medicinal product with an unknown half-life&#xD;
&#xD;
               -  Four weeks of curative radiotherapy&#xD;
&#xD;
               -  Seven days of palliative radiotherapy&#xD;
&#xD;
               -  28 days of radiotherapy&#xD;
&#xD;
          2. Major surgery, locoregional therapy, or radiation therapy within four weeks of the&#xD;
             first dose of derazantinib&#xD;
&#xD;
          3. Previous treatment with any FGFR inhibitor (e.g., Balversa® [erdafitinib], Pemazyre®&#xD;
             [pemigatinib], infigratinib, rogaratinib, futibatinib, lenvatinib, ponatinib,&#xD;
             dovitinib, nintedanib, AZD4547, LY2784455).&#xD;
&#xD;
             - Subjects who received less than four weeks of therapy and were unable to continue&#xD;
             therapy due to toxicity will be allowed to participate&#xD;
&#xD;
          4. Unable or unwilling to swallow the complete daily dose of derazantinib capsules&#xD;
&#xD;
          5. Clinically unstable central nervous system (CNS) metastases (to be eligible, subjects&#xD;
             must have stable disease ≥ 3 months, confirmed by magnetic resonance imaging (MRI) or&#xD;
             computed tomography (CT) scan, and/or have CNS metastases well controlled by low-dose&#xD;
             steroids, anti-epileptics, or other symptom-relieving medications)&#xD;
&#xD;
          6. Current evidence of clinically significant corneal or retinal disorder likely to&#xD;
             increase the risk of eye toxicity, including but not limited to bullous/band&#xD;
             keratopathy, keratoconjunctivitis (unless keratoconjunctivitis sicca), corneal&#xD;
             abrasion, inflammation/ulceration, confirmed by ophthalmologic examination.&#xD;
&#xD;
          7. Concurrent uncontrolled or active hepatobiliary disorders, untreated or ongoing&#xD;
             complications after laparoscopic procedures or stent placement, including but not&#xD;
             limited to active cholangitis, biloma or abscess (to be eligible, the subjects have to&#xD;
             be treated and disorders/complications should be resolved within 2 weeks prior to the&#xD;
             first dose of derazantinib)&#xD;
&#xD;
          8. History of significant cardiac disorders:&#xD;
&#xD;
               -  Myocardial infarction (MI) or congestive heart failure defined as Class II to IV&#xD;
                  per the New York Heart Association (NYHA) classification within 6 months of the&#xD;
                  first dose of derazantinib (MI that occurred &gt; 6 months prior to the first dose&#xD;
                  of derazantinib will be permitted)&#xD;
&#xD;
               -  QTcF &gt;450 msec (males or females)&#xD;
&#xD;
          9. Serum electrolyte abnormalities defined as follows:&#xD;
&#xD;
             - Hyperphosphataemia: Serum phosphate &gt; institutional ULN&#xD;
&#xD;
             - Hyperkalemia: &gt; 6.0 mmol/L&#xD;
&#xD;
             - Hypokalemia: &lt; 3.0 mmol/L&#xD;
&#xD;
             - Hypercalcemia: corrected serum calcium &lt; 1.75 mmol/L (&lt; 7.0 mg/dL)&#xD;
&#xD;
               -  Hypocalcemia: corrected serum calcium &gt; 3.1 mmol/L (&gt; 12.5 mg/dL)&#xD;
&#xD;
               -  Hypomagnesemia: &lt; 0.4 mmol/L (&lt; 0.9 mg/dL)&#xD;
&#xD;
         10. Significant gastrointestinal disorder(s) that could, in the opinion of the&#xD;
             Investigator, interfere with the absorption, metabolism, or excretion of derazantinib&#xD;
             (e.g., Crohn's disease, ulcerative colitis, extensive gastric resection)&#xD;
&#xD;
         11. History of additional malignancy that is progressing or requires active treatment.&#xD;
             Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the&#xD;
             skin that has undergone potentially curative therapy, and in situ cervical cancer.&#xD;
&#xD;
         12. Concurrent uncontrolled illness not related to cancer, including but not limited to:&#xD;
&#xD;
               -  Psychiatric illness/substance abuse/social situation that would limit compliance&#xD;
                  with study requirements&#xD;
&#xD;
               -  Known uncontrolled human immunodeficiency virus (HIV) infection&#xD;
&#xD;
               -  Severe bacterial, fungal, viral and/or parasitic infections on therapeutic oral&#xD;
                  or IV medication at the time of first dose of study drug administration&#xD;
&#xD;
         13. Blood or albumin transfusion within 5 days of the blood draw being used to confirm&#xD;
             eligibility&#xD;
&#xD;
         14. Pregnant or breast feeding&#xD;
&#xD;
         15. Known hypsersensitivity to derazantinib, or to any of the study drug excipients&#xD;
             (starch, lactose, crospovidone, magnesium stearate)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Miryana Dimova-Dobreva, MD</last_name>
    <role>Study Director</role>
    <affiliation>Basilea Pharmaceutica International Ltd</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Miryana Dimova-Dobreva, MD</last_name>
    <phone>+41 76 282 36 90</phone>
    <email>miryana.dimova-dobreva@basilea.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stephan Braun, MD</last_name>
    <phone>+41 79 121 15 61</phone>
    <email>stephan.braun@basilea.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612-9416</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute of Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alicia Escobar, Study Coordinator</last_name>
      <email>alicia.m.escobar@emory.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center - Sidney Kimmel Center for Prostate and Urologic Cancers</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065-6800</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Abramson Cancer Center of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Erasme</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Demols, PI</last_name>
    </contact>
    <contact_backup>
      <last_name>Axelle Ghilain, Study Coordinator</last_name>
      <phone>+32 2 555 44 55</phone>
      <email>axelle.ghilain@erasme.ulb.ac.be</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint-Luc</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Antwerp University Hospital</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Peeters, PI</last_name>
    </contact>
    <contact_backup>
      <last_name>Peggy De Clercq, Study Coordinator</last_name>
      <phone>+32 3 821 53 07</phone>
      <email>peggy.declercq@uza.be</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Tom Baker Cancer Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincent Tam, PI</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Grenoble Alpes</name>
      <address>
        <city>La Tronche</city>
        <zip>38700</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Malka, PI</last_name>
    </contact>
    <contact_backup>
      <last_name>Amal Nacif, Study Coordinator</last_name>
      <phone>+33142116153</phone>
      <email>amal.nacif@gustaveroussy.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Frankfurt</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oliver Waidmann, PI</last_name>
    </contact>
    <contact_backup>
      <last_name>Studienambulanz Medizinische Klinik 1</last_name>
      <phone>+49 69 6301 87769</phone>
      <email>csc.medklinik1@kgu.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf (UKE)</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Henning Wege, PI</last_name>
    </contact>
    <contact_backup>
      <last_name>University Medical Center Hamburg-Eppendorf</last_name>
      <phone>+49 40 7410 57981</phone>
      <email>hcc@uke.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover (MHH)</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum des Saarlandes</name>
      <address>
        <city>Homburg</city>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Universitätsklinikum des Saarlandes Klinik für Innere Medizin II (Studienbüro)</last_name>
      <phone>+49 684116 15288</phone>
    </contact>
    <contact_backup>
      <last_name>OR</last_name>
      <phone>+49 684116 15289</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin der Johannes Gutenberg-Universität Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. James's Hospital</name>
      <address>
        <city>Dublin</city>
        <zip>D08 NHY1</zip>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maeve Lowery, PI</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sant'Orsola-Malpighi Hospital, University of Bologna</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giovanni Brandi, PI</last_name>
    </contact>
    <contact_backup>
      <last_name>Marzia Deserti, Study Coordinator</last_name>
      <email>marzia.deserti2@unibo.it</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Istituto Nazionale dei Tumori</name>
      <address>
        <city>Milan</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincenzo Mazzaferro, PI</last_name>
    </contact>
    <contact_backup>
      <last_name>Emanuela Mazzella, Study Coordinator</last_name>
      <phone>+39 02 23902544</phone>
      <email>emanuela.mazzella@istitutotumori.mi.it</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Ospedale San Gerardo</name>
      <address>
        <city>Monza</city>
        <zip>20900</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Istituto Oncologico Veneto - IRCCS</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria Pisana</name>
      <address>
        <city>Pisa</city>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gianluca Masi, PI</last_name>
    </contact>
    <contact_backup>
      <last_name>Cenar Ahmed, Study Coordinator</last_name>
      <phone>+39 050 99 3841</phone>
      <email>ahmedcenar@gmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Humanitas Cancer Center, Istituto Clinico Humanitas IRCCS</name>
      <address>
        <city>Rozzano</city>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicola Personeni, PI</last_name>
    </contact>
    <contact_backup>
      <last_name>Simona Sala, Study Coordinator</last_name>
      <email>simona.sala@humanitas.it</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>3080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Do-Youn Oh, PI</last_name>
    </contact>
    <contact_backup>
      <last_name>Ja Eun Lee, Study Coordinator</last_name>
      <email>zzarone111@gmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>6351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joon Oh Park, PI</last_name>
    </contact>
    <contact_backup>
      <last_name>Moon Sun Jung, Study Coordinator</last_name>
      <email>moonsun1.jung@samsung.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea, Seoul St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>6591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Myung-Ah Lee, PI</last_name>
    </contact>
    <contact_backup>
      <last_name>Hyunjoo An, Study Coordinator</last_name>
      <email>superexon@daum.net</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Vall d'Hebrón University Hospital</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Teresa Macarulla, PI</last_name>
    </contact>
    <contact_backup>
      <last_name>Marta Beltran, Study Coordinator</last_name>
      <email>mbeltran@vhio.net</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Catalan Institute of Oncology</name>
      <address>
        <city>Barcelona</city>
        <zip>08908</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsspital Basel</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University College London Hospitals NHS Foundation Trust</name>
      <address>
        <city>Euston</city>
        <zip>NW1 2BU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Bridgewater, PI</last_name>
      <email>j.bridgewater@ucl.ac.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beatson West of Scotland Cancer Centre</name>
      <address>
        <city>Glasgow</city>
        <zip>G120YN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeff Evans, PI</last_name>
    </contact>
    <contact_backup>
      <last_name>Jill Graham, Research Nurse</last_name>
      <email>Jill.graham@ggc.scot.nhs.uk</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>The Royal Marsden</name>
      <address>
        <city>Sutton</city>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Cunningham, PI</last_name>
    </contact>
    <contact_backup>
      <last_name>Linda Kirkwood, Study Coordinator</last_name>
      <phone>+44 208 661 3637</phone>
      <email>linda.kirkwood@rmh.nhs.uk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 24, 2017</study_first_submitted>
  <study_first_submitted_qc>July 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2017</study_first_posted>
  <last_update_submitted>August 5, 2021</last_update_submitted>
  <last_update_submitted_qc>August 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>iCCA</keyword>
  <keyword>intrahepatic cholangiocarcinoma</keyword>
  <keyword>FGFR2 gene fusion or FGFR2 gene mutation or amplification</keyword>
  <keyword>biliary cancer</keyword>
  <keyword>bile duct cancer</keyword>
  <keyword>FGFR2 gene rearrangement</keyword>
  <keyword>liver cancer</keyword>
  <keyword>targeted therapy</keyword>
  <keyword>combined hepatocellular and cholangiocarcinoma</keyword>
  <keyword>cHCC-CCA</keyword>
  <keyword>derazantinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangiocarcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

